Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Alder Biopharmaceuticals
Bothell, Washington, United Statesalderbio.com ↗
- Ownership
- Private
- Employees
- ~125
- Development stage
- Other
01
Overview
Alder developed eptinezumab for migraine prevention—demonstrating strong efficacy in clinical trials and ultimately reaching pivotal late-stage development. Other pipeline assets included ALD1910 for migraine and clazakizumab for autoimmune/inflammatory diseases. Eptinezumab showed significant reduction in migraine days and was acquired by H. Lundbeck A/S in a $1.95 billion deal in 2019.
- Therapeutic areas
- OncologyImmunologyNeurology
- Modalities
- monoclonal antibodies (mAbs)genetically engineered therapeutic antibodies
- Industry
- Biotech
02
Partnerships
CSL Limited – collaboration on clazakizumab for solid organ transplant rejectionBristol Myers Squibb – partnership on earlier development of clazakizumab/BMS‑945429
Beyond the preview
Go deeper on Alder Biopharmaceuticals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Alder Biopharmaceuticals.